Cell and Gene Therapy Manufacturing QC Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapy Type (Cell Therapy, Gene Therapy), By Offering (Instruments, Consumables, Others), By Process (Raw Material Preparation, Upstream Processing, Downstream Processing, Packaging), By Technology (Polymerase Chain Reaction (PCR), Flow Cytometry, Limulus Amebocyte Lysate (LAL), Enzyme-Linked Immunosorbent Assay (ELISA), Chromatography, Mass Spectrometry, Western Blotting, Next-Generation Sequencing (NGS), Electrophoresis, Others), By Application (Safety Testing, Potency Testing, Identity Testing, Stability and Genetic Fidelity Testing, Others), By Region and Competition, 2019-2029F
Global Cell and Gene Therapy Manufacturing QC Market was valued at USD 1.04 Billion in 2023 and is anticipated t%li%project steady growth in the forecast period with a CAGR of 6.85% through 2029. The Global Cell and Gene Therapy Manufacturing Quality Control (QC) market encompasses the rapidly evolving sector focused on ensuring the safety, efficacy, and reliability of cell and gene therapy products. Quality control is a critical component in the production process, involving rigorous testing and validation of manufacturing protocols t%li%meet strict regulatory standards. The QC market is driven by the burgeoning demand for advanced therapies targeting complex diseases and relies heavily on cutting-edge technologies for analytics and process standardization.
Key Market Drivers
Rise in Prevalence of Cancer & Cardiovascular Diseases
Cell therapy focuses on different illnesses at the cellular level, either by rejuvenating a specific cell group or by utilizing cells as carriers for therapeutic agents. Whereas gene therapy seeks t%li%impact the progression of various genetic and acquired conditions at the genetic level. It is expected that cardiovascular ailments will propel the demand for cell and gene therapies which will in turn drive the growth of cell and gene therapy manufacturing QC market in the forecast period. One possible treatment which have emerged as a leading option for management of cardiac arrhythmias are approaches which can improve the action potential conduction and electrical excitability in the heart.
Stem cell therapy has the significant potential t%li%treat cardiac diseases mainly heart failure and coronary heart diseases. Numerous clinical trials have depicted that stem cell therapies are safe t%li%use and acquire the extensive capability t%li%improve the heart function thereby reducing the chances of adverse cardiovascular events. Cancer have als%li%prevailed as a leading morbidity over past few years. In tw%li%latest clinical trials which were conducted in 2022, it has been proved that CAR T-cell therapy can als%li%be used for management of non-Hodgkin lymphoma in patients whose cancer returned after initial stage. Therefore, development of new cell and new therapies which are making new additions in treatment techniques of serious chronic diseases are als%li%anticipated t%li%bolster the growth of cell and gene therapy manufacturing QC market in the forecast period.
Growth in Pharmaceutical Research & Development
Cell and gene therapies are a rapidly expanding domain of medicine with the capability t%li%cure a broad spectrum of ailments. Nevertheless, these therapies are als%li%inherently complex and require rigorous quality assurance (QA) measures t%li%ensure their well-being and effectiveness. Research and development in the quality control of cell and gene therapies is concentrated on developing novel approaches and technologies that can enhance the precision, effectiveness, and promptness of quality control testing. Many new methods have been developed in recent years t%li%facilitate the QC of cell and gene therapies. Scientists at the University of Pennsylvania created a novel technique for characterizing the efficacy of cellular and genetic treatments. This technique is known as functional evaluations which enables the quantification of cells' capacity t%li%carry out designated functions, such as combating infections or generating proteins.
Increasing Pipeline of Therapies
The burgeoning pipeline of innovative therapies, particularly in the realm of cell and gene therapy, is catalyzing a surge in demand for robust quality control (QC) solutions worldwide. With an increasing number of biopharmaceutical companies focusing on developing cutting-edge cell and gene therapies t%li%address a diverse array of diseases, there's a pressing need for stringent QC measures t%li%ensure safety, efficacy, and consistency of these treatments. The complexity of cell and gene therapies, often tailored t%li%individual patients, necessitates meticulous QC protocols throughout the manufacturing process. T
he demand for specialized QC technologies and services tailored t%li%the unique requirements of cell and gene therapy manufacturing is on the rise. This trend is driving significant growth in the global Cell and Gene Therapy Manufacturing QC Market, as companies seek reliable QC solutions t%li%navigate the intricate regulatory landscape and bring innovative therapies t%li%market efficiently and safely.
Manufacturing Scale-up
The process of scaling up manufacturing operations for cell and gene therapies is presenting a formidable challenge, one that significantly amplifies the demand for robust quality control (QC) solutions on a global scale. As promising therapies progress from early-stage development t%li%commercial production, the need for stringent QC measures becomes paramount t%li%ensure product quality, safety, and consistency at larger scales. Manufacturing scale-up introduces complexities such as optimizing production processes, increasing batch sizes, and maintaining uniformity across multiple manufacturing sites—all of which require meticulous QC protocols. Consequently, biopharmaceutical companies are increasingly investing in advanced QC technologies and expertise tailored specifically for cell and gene therapy manufacturing. This surge in demand for QC solutions is propelling the growth of the global Cell and Gene Therapy Manufacturing QC Market, as companies strive t%li%meet regulatory requirements, minimize risks, and accelerate the commercialization of life-saving therapies.
Key Market Challenges
Shortage Of Professionals Skilled in Advanced Manufacturing & Quality Control of Gene & Cell Therapies
Strict adherence t%li%quality assurance (QA) standards within the cell and gene therapy manufacturing sector may paradoxically decrease the demand for traditional quality control (QC) solutions globally. As regulatory agencies enforce stringent QA requirements t%li%ensure the safety and efficacy of therapies, companies are compelled t%li%implement comprehensive QA measures throughout the manufacturing process. This robust QA framework often incorporates built-in quality control mechanisms, reducing the need for separate QC systems. Advancements in manufacturing technologies and process optimization allow for greater consistency and reliability, minimizing the occurrence of errors and deviations that typically necessitate extensive QC interventions. There may be a shift towards integrated QA-QC approaches, where QC functions are seamlessly embedded within QA processes, leading t%li%a potential decrease in the demand for standalone QC solutions in the cell and gene therapy manufacturing market as companies prioritize holistic quality assurance strategies.
High Cost of Quality Control
The high cost associated with quality control (QC) processes in cell and gene therapy manufacturing could potentially decrease the demand for QC solutions globally. While QC is crucial for ensuring the safety, efficacy, and consistency of therapies, the significant expenses involve. The complexity of cell and gene therapies, often requiring specialized QC technologies and expertise, can further inflate the costs of QC implementation and maintenance. Companies might opt t%li%prioritize cost-saving measures or alternative QC strategies, such as outsourcing QC functions or utilizing less expensive QC technologies, potentially leading t%li%a decreased demand for traditional QC solutions in the cell and gene therapy manufacturing market. This cost-conscious approach could shape the dynamics of the QC market as companies balance the need for quality assurance with financial constraints.
Key Market Trends
Strict Adherence t%li%QA Standards
The stringent adherence t%li%quality assurance (QA) standards within the cell and gene therapy manufacturing sector is playing a pivotal role in driving the demand for advanced quality control (QC) solutions on a global scale. As regulatory agencies impose rigorous requirements t%li%ensure the safety, efficacy, and consistency of these groundbreaking therapies, biopharmaceutical companies are under increasing pressure t%li%implement comprehensive QA measures throughout the manufacturing process. Strict adherence t%li%QA standards necessitates robust QC protocols t%li%detect and mitigate any deviations or discrepancies promptly. Consequently, there's a growing demand for specialized QC technologies and services tailored specifically for the unique challenges of cell and gene therapy manufacturing. This escalating demand for QC solutions is fueling the expansion of the global Cell and Gene Therapy Manufacturing QC Market as companies prioritize compliance with QA standards t%li%navigate regulatory complexities, uphold product quality, and accelerate the development and commercialization of transformative therapies.
Use of Technologies like AI In QC Systems
The integration of cutting-edge technologies, such as artificial intelligence (AI), int%li%quality control (QC) systems, is revolutionizing the cell and gene therapy manufacturing landscape and significantly bolstering the demand for advanced QC solutions worldwide. AI-powered QC systems offer unprecedented capabilities for data analysis, predictive modeling, and real-time monitoring, enabling biopharmaceutical companies t%li%enhance the efficiency, accuracy, and reliability of their QC processes. By leveraging AI algorithms t%li%analyze vast datasets and identify patterns or anomalies, these systems can streamline QC protocols, accelerate decision-making, and mitigate risks during the manufacturing of complex cell and gene therapies. There's a surging demand for AI-driven QC technologies and services tailored specifically for the unique requirements of cell and gene therapy manufacturing. This increasing reliance on AI in QC systems is driving the growth of the global Cell and Gene Therapy Manufacturing QC Market as companies recognize the transformative potential of technology t%li%optimize production processes, ensure regulatory compliance, and expedite the development and commercialization of innovative therapies.
Segmental Insights
Therapy Type Insights
Based on Therapy Type, gene therapy has gained rapid growth in the global cell and gene therapy manufacturing quality control (QC) market in 2023. This growing trend can be attributed t%li%several factors. The increasing approval of gene therapy products by regulatory authorities has provided a strong foundation for the sector's expansion. Substantial investments in research and development (R&D) have fuelled advancements in gene therapy, leading t%li%breakthrough treatments and therapies. The rising demand for regenerative medicine has further fuelled the growth of gene therapy as it offers the potential t%li%address the root causes of genetic disorders. The impact of gene therapies goes beyond conventional treatments, as they are revolutionizing the fight against previously untreatable conditions.
By targeting the underlying genetic mechanisms, gene therapies offer new hope and possibilities for patients wh%li%have long struggled with debilitating disorders. This revolutionary approach has garnered significant interest from both the public and private sectors, driving further investment and research in this field. As the field of gene therapy continues t%li%evolve, it holds immense promise for the future of medicine. With ongoing advancements, we can look forward t%li%more targeted and effective treatments that could potentially transform the lives of countless individuals worldwide.
Offering Insights
Based on the Offering, within the global Cell and Gene Therapy Manufacturing Quality Control (QC) market, the Instruments segment is currently dominating in terms of market share. Cell and gene therapy manufacturing entails complex processes that demand precise quality control measures at each stage. Instruments are vital in guaranteeing the quality, purity, and effectiveness of therapeutic products, rendering them indispensable for manufacturers. Regulatory bodies impose rigorous quality control standards t%li%ensure the safety and efficacy of cell and gene therapy products. Instruments provide dependable and standardized methodologies t%li%meet these regulatory requirements, making them indispensable for achieving compliance and securing market approval. The rapid progress of technology has spurred the creation of advanced instruments tailored specifically for cell and gene therapy manufacturing QC. These instruments offer heightened sensitivity, accuracy, and throughput, empowering manufacturers t%li%identify and rectify quality issues more efficiently. Automation plays a pivotal role in optimizing manufacturing processes and minimizing human error. Instruments equipped with automation capabilities facilitate streamlined sample processing, data analysis, and reporting, thereby enhancing overall QC effectiveness and productivity.
Regional Insights
North America has firmly established itself as the dominating region in the global market for cell and gene therapy manufacturing quality control (QC). This leadership position can be attributed t%li%its highly advanced biotechnology infrastructure, which includes state-of-the-art research facilities, cutting-edge manufacturing capabilities, and a robust talent pool of scientists and experts. Substantial investments in research and development have propelled North America t%li%the forefront of innovation in this field.
North America boasts a comprehensive regulatory framework that ensures the highest standards of safety and efficacy in therapeutic practices. These regulatory frameworks, meticulously designed and continuously updated, provide a solid foundation for the development and manufacturing of cell and gene therapies. The stringent regulations and rigorous quality control measures in place inspire confidence in the safety and effectiveness of these therapies, not only within North America but als%li%internationally.
With its unwavering commitment t%li%excellence and continuous advancements in technology, North America continues t%li%raise the bar in the field of cell and gene therapy manufacturing quality control. The region's relentless pursuit of breakthroughs, coupled with its collaborative ecosystem of academia, industry, and regulatory bodies, fosters a fertile ground for innovation and ensures that North America remains at the forefront of this rapidly evolving field.
Regional Insights
In this report, the Global Cell and Gene Therapy Manufacturing QC Market has been segmented int%li%the following categories, in addition t%li%the industry trends which have als%li%been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Cell and Gene Therapy Manufacturing QC Market.
Available Customizations:
Global Cell and Gene Therapy Manufacturing QC Market report with the given market data, Tech Sci Research offers customizations according t%li%a company's specific needs. The following customization options are available for the report:
Company Information
Key Market Drivers
Rise in Prevalence of Cancer & Cardiovascular Diseases
Cell therapy focuses on different illnesses at the cellular level, either by rejuvenating a specific cell group or by utilizing cells as carriers for therapeutic agents. Whereas gene therapy seeks t%li%impact the progression of various genetic and acquired conditions at the genetic level. It is expected that cardiovascular ailments will propel the demand for cell and gene therapies which will in turn drive the growth of cell and gene therapy manufacturing QC market in the forecast period. One possible treatment which have emerged as a leading option for management of cardiac arrhythmias are approaches which can improve the action potential conduction and electrical excitability in the heart.
Stem cell therapy has the significant potential t%li%treat cardiac diseases mainly heart failure and coronary heart diseases. Numerous clinical trials have depicted that stem cell therapies are safe t%li%use and acquire the extensive capability t%li%improve the heart function thereby reducing the chances of adverse cardiovascular events. Cancer have als%li%prevailed as a leading morbidity over past few years. In tw%li%latest clinical trials which were conducted in 2022, it has been proved that CAR T-cell therapy can als%li%be used for management of non-Hodgkin lymphoma in patients whose cancer returned after initial stage. Therefore, development of new cell and new therapies which are making new additions in treatment techniques of serious chronic diseases are als%li%anticipated t%li%bolster the growth of cell and gene therapy manufacturing QC market in the forecast period.
Growth in Pharmaceutical Research & Development
Cell and gene therapies are a rapidly expanding domain of medicine with the capability t%li%cure a broad spectrum of ailments. Nevertheless, these therapies are als%li%inherently complex and require rigorous quality assurance (QA) measures t%li%ensure their well-being and effectiveness. Research and development in the quality control of cell and gene therapies is concentrated on developing novel approaches and technologies that can enhance the precision, effectiveness, and promptness of quality control testing. Many new methods have been developed in recent years t%li%facilitate the QC of cell and gene therapies. Scientists at the University of Pennsylvania created a novel technique for characterizing the efficacy of cellular and genetic treatments. This technique is known as functional evaluations which enables the quantification of cells' capacity t%li%carry out designated functions, such as combating infections or generating proteins.
Increasing Pipeline of Therapies
The burgeoning pipeline of innovative therapies, particularly in the realm of cell and gene therapy, is catalyzing a surge in demand for robust quality control (QC) solutions worldwide. With an increasing number of biopharmaceutical companies focusing on developing cutting-edge cell and gene therapies t%li%address a diverse array of diseases, there's a pressing need for stringent QC measures t%li%ensure safety, efficacy, and consistency of these treatments. The complexity of cell and gene therapies, often tailored t%li%individual patients, necessitates meticulous QC protocols throughout the manufacturing process. T
he demand for specialized QC technologies and services tailored t%li%the unique requirements of cell and gene therapy manufacturing is on the rise. This trend is driving significant growth in the global Cell and Gene Therapy Manufacturing QC Market, as companies seek reliable QC solutions t%li%navigate the intricate regulatory landscape and bring innovative therapies t%li%market efficiently and safely.
Manufacturing Scale-up
The process of scaling up manufacturing operations for cell and gene therapies is presenting a formidable challenge, one that significantly amplifies the demand for robust quality control (QC) solutions on a global scale. As promising therapies progress from early-stage development t%li%commercial production, the need for stringent QC measures becomes paramount t%li%ensure product quality, safety, and consistency at larger scales. Manufacturing scale-up introduces complexities such as optimizing production processes, increasing batch sizes, and maintaining uniformity across multiple manufacturing sites—all of which require meticulous QC protocols. Consequently, biopharmaceutical companies are increasingly investing in advanced QC technologies and expertise tailored specifically for cell and gene therapy manufacturing. This surge in demand for QC solutions is propelling the growth of the global Cell and Gene Therapy Manufacturing QC Market, as companies strive t%li%meet regulatory requirements, minimize risks, and accelerate the commercialization of life-saving therapies.
Key Market Challenges
Shortage Of Professionals Skilled in Advanced Manufacturing & Quality Control of Gene & Cell Therapies
Strict adherence t%li%quality assurance (QA) standards within the cell and gene therapy manufacturing sector may paradoxically decrease the demand for traditional quality control (QC) solutions globally. As regulatory agencies enforce stringent QA requirements t%li%ensure the safety and efficacy of therapies, companies are compelled t%li%implement comprehensive QA measures throughout the manufacturing process. This robust QA framework often incorporates built-in quality control mechanisms, reducing the need for separate QC systems. Advancements in manufacturing technologies and process optimization allow for greater consistency and reliability, minimizing the occurrence of errors and deviations that typically necessitate extensive QC interventions. There may be a shift towards integrated QA-QC approaches, where QC functions are seamlessly embedded within QA processes, leading t%li%a potential decrease in the demand for standalone QC solutions in the cell and gene therapy manufacturing market as companies prioritize holistic quality assurance strategies.
High Cost of Quality Control
The high cost associated with quality control (QC) processes in cell and gene therapy manufacturing could potentially decrease the demand for QC solutions globally. While QC is crucial for ensuring the safety, efficacy, and consistency of therapies, the significant expenses involve. The complexity of cell and gene therapies, often requiring specialized QC technologies and expertise, can further inflate the costs of QC implementation and maintenance. Companies might opt t%li%prioritize cost-saving measures or alternative QC strategies, such as outsourcing QC functions or utilizing less expensive QC technologies, potentially leading t%li%a decreased demand for traditional QC solutions in the cell and gene therapy manufacturing market. This cost-conscious approach could shape the dynamics of the QC market as companies balance the need for quality assurance with financial constraints.
Key Market Trends
Strict Adherence t%li%QA Standards
The stringent adherence t%li%quality assurance (QA) standards within the cell and gene therapy manufacturing sector is playing a pivotal role in driving the demand for advanced quality control (QC) solutions on a global scale. As regulatory agencies impose rigorous requirements t%li%ensure the safety, efficacy, and consistency of these groundbreaking therapies, biopharmaceutical companies are under increasing pressure t%li%implement comprehensive QA measures throughout the manufacturing process. Strict adherence t%li%QA standards necessitates robust QC protocols t%li%detect and mitigate any deviations or discrepancies promptly. Consequently, there's a growing demand for specialized QC technologies and services tailored specifically for the unique challenges of cell and gene therapy manufacturing. This escalating demand for QC solutions is fueling the expansion of the global Cell and Gene Therapy Manufacturing QC Market as companies prioritize compliance with QA standards t%li%navigate regulatory complexities, uphold product quality, and accelerate the development and commercialization of transformative therapies.
Use of Technologies like AI In QC Systems
The integration of cutting-edge technologies, such as artificial intelligence (AI), int%li%quality control (QC) systems, is revolutionizing the cell and gene therapy manufacturing landscape and significantly bolstering the demand for advanced QC solutions worldwide. AI-powered QC systems offer unprecedented capabilities for data analysis, predictive modeling, and real-time monitoring, enabling biopharmaceutical companies t%li%enhance the efficiency, accuracy, and reliability of their QC processes. By leveraging AI algorithms t%li%analyze vast datasets and identify patterns or anomalies, these systems can streamline QC protocols, accelerate decision-making, and mitigate risks during the manufacturing of complex cell and gene therapies. There's a surging demand for AI-driven QC technologies and services tailored specifically for the unique requirements of cell and gene therapy manufacturing. This increasing reliance on AI in QC systems is driving the growth of the global Cell and Gene Therapy Manufacturing QC Market as companies recognize the transformative potential of technology t%li%optimize production processes, ensure regulatory compliance, and expedite the development and commercialization of innovative therapies.
Segmental Insights
Therapy Type Insights
Based on Therapy Type, gene therapy has gained rapid growth in the global cell and gene therapy manufacturing quality control (QC) market in 2023. This growing trend can be attributed t%li%several factors. The increasing approval of gene therapy products by regulatory authorities has provided a strong foundation for the sector's expansion. Substantial investments in research and development (R&D) have fuelled advancements in gene therapy, leading t%li%breakthrough treatments and therapies. The rising demand for regenerative medicine has further fuelled the growth of gene therapy as it offers the potential t%li%address the root causes of genetic disorders. The impact of gene therapies goes beyond conventional treatments, as they are revolutionizing the fight against previously untreatable conditions.
By targeting the underlying genetic mechanisms, gene therapies offer new hope and possibilities for patients wh%li%have long struggled with debilitating disorders. This revolutionary approach has garnered significant interest from both the public and private sectors, driving further investment and research in this field. As the field of gene therapy continues t%li%evolve, it holds immense promise for the future of medicine. With ongoing advancements, we can look forward t%li%more targeted and effective treatments that could potentially transform the lives of countless individuals worldwide.
Offering Insights
Based on the Offering, within the global Cell and Gene Therapy Manufacturing Quality Control (QC) market, the Instruments segment is currently dominating in terms of market share. Cell and gene therapy manufacturing entails complex processes that demand precise quality control measures at each stage. Instruments are vital in guaranteeing the quality, purity, and effectiveness of therapeutic products, rendering them indispensable for manufacturers. Regulatory bodies impose rigorous quality control standards t%li%ensure the safety and efficacy of cell and gene therapy products. Instruments provide dependable and standardized methodologies t%li%meet these regulatory requirements, making them indispensable for achieving compliance and securing market approval. The rapid progress of technology has spurred the creation of advanced instruments tailored specifically for cell and gene therapy manufacturing QC. These instruments offer heightened sensitivity, accuracy, and throughput, empowering manufacturers t%li%identify and rectify quality issues more efficiently. Automation plays a pivotal role in optimizing manufacturing processes and minimizing human error. Instruments equipped with automation capabilities facilitate streamlined sample processing, data analysis, and reporting, thereby enhancing overall QC effectiveness and productivity.
Regional Insights
North America has firmly established itself as the dominating region in the global market for cell and gene therapy manufacturing quality control (QC). This leadership position can be attributed t%li%its highly advanced biotechnology infrastructure, which includes state-of-the-art research facilities, cutting-edge manufacturing capabilities, and a robust talent pool of scientists and experts. Substantial investments in research and development have propelled North America t%li%the forefront of innovation in this field.
North America boasts a comprehensive regulatory framework that ensures the highest standards of safety and efficacy in therapeutic practices. These regulatory frameworks, meticulously designed and continuously updated, provide a solid foundation for the development and manufacturing of cell and gene therapies. The stringent regulations and rigorous quality control measures in place inspire confidence in the safety and effectiveness of these therapies, not only within North America but als%li%internationally.
With its unwavering commitment t%li%excellence and continuous advancements in technology, North America continues t%li%raise the bar in the field of cell and gene therapy manufacturing quality control. The region's relentless pursuit of breakthroughs, coupled with its collaborative ecosystem of academia, industry, and regulatory bodies, fosters a fertile ground for innovation and ensures that North America remains at the forefront of this rapidly evolving field.
Regional Insights
- In January 2023, Bio-Techne Corporation launched MauriceFlex, a novel addition t%li%its ProteinSimple product line. MauriceFlex is a versatile platform designed t%li%facilitate the separation of protein charge variants, expanding upon standard cIEF (capillary isoelectric focusing) and CE-SDS (capillary electrophoresis-sodium dodecyl sulfate) tests. This innovative system provides comprehensive protein characterization, streamlining examination procedures.
- Bio-Techne Corporation
- Biomerieux SA
- F. Hoffmann-La Roche Ltd
- Lonza Group Ltd.
- Miltenyi Biotec India Pvt Ltd.
- Sartorius AG
- Therm%li%Fisher Scientific Inc.
- AGC Inc.
- Charles River Laboratories International, Inc.
- Merck KGaA
In this report, the Global Cell and Gene Therapy Manufacturing QC Market has been segmented int%li%the following categories, in addition t%li%the industry trends which have als%li%been detailed below:
- Cell and Gene Therapy Manufacturing QC Market, By Therapy Type:
- Cell Therapy
- Gene Therapy
- Cell and Gene Therapy Manufacturing QC Market, By Offering:
- Instruments
- Consumables
- Others
- Cell and Gene Therapy Manufacturing QC Market, By Process:
- Raw Material Preparation
- Upstream Processing
- Downstream Processing
- Packaging
- Cell and Gene Therapy Manufacturing QC Market, By Technology:
- Polymerase Chain Reaction (PCR)
- Flow Cytometry
- Limulus Amebocyte Lysate (LAL)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Chromatography
- Mass Spectrometry
- Western Blotting
- Next-Generation Sequencing (NGS)
- Electrophoresis
- Others
- Cell and Gene Therapy Manufacturing QC Market, By Application:
- Safety Testing
- Potency Testing
- Identity Testing
- Stability and Genetic Fidelity Testing
- Others
- Cell and Gene Therapy Manufacturing QC Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in the Global Cell and Gene Therapy Manufacturing QC Market.
Available Customizations:
Global Cell and Gene Therapy Manufacturing QC Market report with the given market data, Tech Sci Research offers customizations according t%li%a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up t%li%five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. GLOBAL CELL AND GENE THERAPY MANUFACTURING QC MARKET OUTLOOK
4.1. Market Size & Forecast
4.1.1. By Value
4.2. Market Share & Forecast
4.2.1. By Therapy Type (Cell Therapy, Gene Therapy)
4.2.2. By Offering (Instruments, Consumables, Others)
4.2.3. By Process (Raw Material Preparation, Upstream Processing, Downstream Processing, Packaging)
4.2.4. By Technology (Polymerase Chain Reaction (PCR), Flow Cytometry, Limulus Amebocyte Lysate (LAL), Enzyme-Linked Immunosorbent Assay (ELISA), Chromatography, Mass Spectrometry, Western Blotting, Next-Generation Sequencing (NGS), Electrophoresis, Others)
4.2.5. By Application (Safety Testing, Potency Testing, Identity Testing, Stability and Genetic Fidelity Testing, Others)
4.2.6. By Region
4.2.7. By Company (2023)
4.3. Market Map
5. NORTH AMERICA CELL AND GENE THERAPY MANUFACTURING QC MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Therapy Type
5.2.2. By Offering
5.2.3. By Process
5.2.4. By Technology
5.2.5. By Application
5.2.6. By Country
5.3. North America: Country Analysis
5.3.1. United States Cell and Gene Therapy Manufacturing QC Market Outlook
5.3.1.1. Market Size & Forecast
5.3.1.1.1. By Value
5.3.1.2. Market Share & Forecast
5.3.1.2.1. By Therapy Type
5.3.1.2.2. By Offering
5.3.1.2.3. By Process
5.3.1.2.4. By Technology
5.3.1.2.5. By Application
5.3.2. Mexico Cell and Gene Therapy Manufacturing QC Market Outlook
5.3.2.1. Market Size & Forecast
5.3.2.1.1. By Value
5.3.2.2. Market Share & Forecast
5.3.2.2.1. By Therapy Type
5.3.2.2.2. By Offering
5.3.2.2.3. By Process
5.3.2.2.4. By Technology
5.3.2.2.5. By Application
5.3.3. Canada Cell and Gene Therapy Manufacturing QC Market Outlook
5.3.3.1. Market Size & Forecast
5.3.3.1.1. By Value
5.3.3.2. Market Share & Forecast
5.3.3.2.1. By Therapy Type
5.3.3.2.2. By Offering
5.3.3.2.3. By Process
5.3.3.2.4. By Technology
5.3.3.2.5. By Application
6. EUROPE CELL AND GENE THERAPY MANUFACTURING QC MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Therapy Type
6.2.2. By Offering
6.2.3. By Process
6.2.4. By Technology
6.2.5. By Application
6.2.6. By Country
6.3 Europe: Country Analysis
6.3.1. France Cell and Gene Therapy Manufacturing QC Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Therapy Type
6.3.1.2.2. By Offering
6.3.1.2.3. By Process
6.3.1.2.4. By Technology
6.3.1.2.5. By Application
6.3.2. Germany Cell and Gene Therapy Manufacturing QC Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Therapy Type
6.3.2.2.2. By Offering
6.3.2.2.3. By Process
6.3.2.2.4. By Technology
6.3.2.2.5. By Application
6.3.3. United Kingdom Cell and Gene Therapy Manufacturing QC Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Therapy Type
6.3.3.2.2. By Offering
6.3.3.2.3. By Process
6.3.3.2.4. By Technology
6.3.3.2.5. By Application
6.3.4. Italy Cell and Gene Therapy Manufacturing QC Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Therapy Type
6.3.4.2.2. By Offering
6.3.4.2.3. By Process
6.3.4.2.4. By Technology
6.3.4.2.5. By Application
6.3.5. Spain Cell and Gene Therapy Manufacturing QC Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Therapy Type
6.3.5.2.2. By Offering
6.3.5.2.3. By Process
6.3.5.2.4. By Technology
6.3.5.2.5. By Application
7. ASIA-PACIFIC CELL AND GENE THERAPY MANUFACTURING QC MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Therapy Type
7.2.2. By Offering
7.2.3. By Process
7.2.4. By Technology
7.2.5. By Application
7.2.6. By Country
7.3. Asia-Pacific: Country Analysis
7.3.1. China Cell and Gene Therapy Manufacturing QC Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Therapy Type
7.3.1.2.2. By Offering
7.3.1.2.3. By Process
7.3.1.2.4. By Technology
7.3.1.2.5. By Application
7.3.2. India Cell and Gene Therapy Manufacturing QC Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Therapy Type
7.3.2.2.2. By Offering
7.3.2.2.3. By Process
7.3.2.2.4. By Technology
7.3.2.2.5. By Application
7.3.3. South Korea Cell and Gene Therapy Manufacturing QC Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Therapy Type
7.3.3.2.2. By Offering
7.3.3.2.3. By Process
7.3.3.2.4. By Technology
7.3.3.2.5. By Application
7.3.4. Japan Cell and Gene Therapy Manufacturing QC Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Therapy Type
7.3.4.2.2. By Offering
7.3.4.2.3. By Process
7.3.4.2.4. By Technology
7.3.4.2.5. By Application
7.3.5. Australia Cell and Gene Therapy Manufacturing QC Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Therapy Type
7.3.5.2.2. By Offering
7.3.5.2.3. By Process
7.3.5.2.4. By Technology
7.3.5.2.5. By Application
8. SOUTH AMERICA CELL AND GENE THERAPY MANUFACTURING QC MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Therapy Type
8.2.2. By Offering
8.2.3. By Process
8.2.4. By Technology
8.2.5. By Application
8.2.6. By Country
8.3. South America: Country Analysis
8.3.1. Brazil Cell and Gene Therapy Manufacturing QC Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Therapy Type
8.3.1.2.2. By Offering
8.3.1.2.3. By Process
8.3.1.2.4. By Technology
8.3.1.2.5. By Application
8.3.2. Argentina Cell and Gene Therapy Manufacturing QC Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Therapy Type
8.3.2.2.2. By Offering
8.3.2.2.3. By Process
8.3.2.2.4. By Technology
8.3.2.2.5. By Application
8.3.3. Colombia Cell and Gene Therapy Manufacturing QC Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Therapy Type
8.3.3.2.2. By Offering
8.3.3.2.3. By Process
8.3.3.2.4. By Technology
8.3.3.2.5. By Application
9. MIDDLE EAST AND AFRICA CELL AND GENE THERAPY MANUFACTURING QC MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Therapy Type
9.2.2. By Offering
9.2.3. By Process
9.2.4. By Technology
9.2.5. By Application
9.2.6. By Country
9.3. MEA: Country Analysis
9.3.1. South Africa Cell and Gene Therapy Manufacturing QC Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Therapy Type
9.3.1.2.2. By Offering
9.3.1.2.3. By Process
9.3.1.2.4. By Technology
9.3.1.2.5. By Application
9.3.2. Saudi Arabia Cell and Gene Therapy Manufacturing QC Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Therapy Type
9.3.2.2.2. By Offering
9.3.2.2.3. By Process
9.3.2.2.4. By Technology
9.3.2.2.5. By Application
9.3.3. UAE Cell and Gene Therapy Manufacturing QC Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Therapy Type
9.3.3.2.2. By Offering
9.3.3.2.3. By Process
9.3.3.2.4. By Technology
9.3.3.2.5. By Application
10. MARKET DYNAMICS
10.1. Drivers
10.2. Challenges
11. MARKET TRENDS & DEVELOPMENTS
11.1. Merger & Acquisition (If Any)
11.2. Product Launches (If Any)
11.3. Recent Developments
12. PESTLE ANALYSIS
13. PORTER’S FIVE FORCES ANALYSIS
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Product
14. COMPETITIVE LANDSCAPE
14.1. Bio-Techne Corporation
14.1.1. Business Overview
14.1.2. Company Snapshot
14.1.3. Products & Services
14.1.4. Financials (As Reported)
14.1.5. Recent Developments
14.1.6. Key Personnel Details
14.1.7. SWOT Analysis
14.2. Biomerieux SA
14.3. F. Hoffmann-La Roche Ltd
14.4. Lonza Group Ltd.
14.5. Miltenyi Biotec India Pvt Ltd.
14.6. Sartorius AG
14.7. Thermo Fisher Scientific Inc.
14.8. AGC Inc.
14.9. Charles River Laboratories International, Inc.
14.10. Merck KGaA
15. STRATEGIC RECOMMENDATIONS
16. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. GLOBAL CELL AND GENE THERAPY MANUFACTURING QC MARKET OUTLOOK
4.1. Market Size & Forecast
4.1.1. By Value
4.2. Market Share & Forecast
4.2.1. By Therapy Type (Cell Therapy, Gene Therapy)
4.2.2. By Offering (Instruments, Consumables, Others)
4.2.3. By Process (Raw Material Preparation, Upstream Processing, Downstream Processing, Packaging)
4.2.4. By Technology (Polymerase Chain Reaction (PCR), Flow Cytometry, Limulus Amebocyte Lysate (LAL), Enzyme-Linked Immunosorbent Assay (ELISA), Chromatography, Mass Spectrometry, Western Blotting, Next-Generation Sequencing (NGS), Electrophoresis, Others)
4.2.5. By Application (Safety Testing, Potency Testing, Identity Testing, Stability and Genetic Fidelity Testing, Others)
4.2.6. By Region
4.2.7. By Company (2023)
4.3. Market Map
5. NORTH AMERICA CELL AND GENE THERAPY MANUFACTURING QC MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Therapy Type
5.2.2. By Offering
5.2.3. By Process
5.2.4. By Technology
5.2.5. By Application
5.2.6. By Country
5.3. North America: Country Analysis
5.3.1. United States Cell and Gene Therapy Manufacturing QC Market Outlook
5.3.1.1. Market Size & Forecast
5.3.1.1.1. By Value
5.3.1.2. Market Share & Forecast
5.3.1.2.1. By Therapy Type
5.3.1.2.2. By Offering
5.3.1.2.3. By Process
5.3.1.2.4. By Technology
5.3.1.2.5. By Application
5.3.2. Mexico Cell and Gene Therapy Manufacturing QC Market Outlook
5.3.2.1. Market Size & Forecast
5.3.2.1.1. By Value
5.3.2.2. Market Share & Forecast
5.3.2.2.1. By Therapy Type
5.3.2.2.2. By Offering
5.3.2.2.3. By Process
5.3.2.2.4. By Technology
5.3.2.2.5. By Application
5.3.3. Canada Cell and Gene Therapy Manufacturing QC Market Outlook
5.3.3.1. Market Size & Forecast
5.3.3.1.1. By Value
5.3.3.2. Market Share & Forecast
5.3.3.2.1. By Therapy Type
5.3.3.2.2. By Offering
5.3.3.2.3. By Process
5.3.3.2.4. By Technology
5.3.3.2.5. By Application
6. EUROPE CELL AND GENE THERAPY MANUFACTURING QC MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Therapy Type
6.2.2. By Offering
6.2.3. By Process
6.2.4. By Technology
6.2.5. By Application
6.2.6. By Country
6.3 Europe: Country Analysis
6.3.1. France Cell and Gene Therapy Manufacturing QC Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Therapy Type
6.3.1.2.2. By Offering
6.3.1.2.3. By Process
6.3.1.2.4. By Technology
6.3.1.2.5. By Application
6.3.2. Germany Cell and Gene Therapy Manufacturing QC Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Therapy Type
6.3.2.2.2. By Offering
6.3.2.2.3. By Process
6.3.2.2.4. By Technology
6.3.2.2.5. By Application
6.3.3. United Kingdom Cell and Gene Therapy Manufacturing QC Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Therapy Type
6.3.3.2.2. By Offering
6.3.3.2.3. By Process
6.3.3.2.4. By Technology
6.3.3.2.5. By Application
6.3.4. Italy Cell and Gene Therapy Manufacturing QC Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Therapy Type
6.3.4.2.2. By Offering
6.3.4.2.3. By Process
6.3.4.2.4. By Technology
6.3.4.2.5. By Application
6.3.5. Spain Cell and Gene Therapy Manufacturing QC Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Therapy Type
6.3.5.2.2. By Offering
6.3.5.2.3. By Process
6.3.5.2.4. By Technology
6.3.5.2.5. By Application
7. ASIA-PACIFIC CELL AND GENE THERAPY MANUFACTURING QC MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Therapy Type
7.2.2. By Offering
7.2.3. By Process
7.2.4. By Technology
7.2.5. By Application
7.2.6. By Country
7.3. Asia-Pacific: Country Analysis
7.3.1. China Cell and Gene Therapy Manufacturing QC Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Therapy Type
7.3.1.2.2. By Offering
7.3.1.2.3. By Process
7.3.1.2.4. By Technology
7.3.1.2.5. By Application
7.3.2. India Cell and Gene Therapy Manufacturing QC Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Therapy Type
7.3.2.2.2. By Offering
7.3.2.2.3. By Process
7.3.2.2.4. By Technology
7.3.2.2.5. By Application
7.3.3. South Korea Cell and Gene Therapy Manufacturing QC Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Therapy Type
7.3.3.2.2. By Offering
7.3.3.2.3. By Process
7.3.3.2.4. By Technology
7.3.3.2.5. By Application
7.3.4. Japan Cell and Gene Therapy Manufacturing QC Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Therapy Type
7.3.4.2.2. By Offering
7.3.4.2.3. By Process
7.3.4.2.4. By Technology
7.3.4.2.5. By Application
7.3.5. Australia Cell and Gene Therapy Manufacturing QC Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Therapy Type
7.3.5.2.2. By Offering
7.3.5.2.3. By Process
7.3.5.2.4. By Technology
7.3.5.2.5. By Application
8. SOUTH AMERICA CELL AND GENE THERAPY MANUFACTURING QC MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Therapy Type
8.2.2. By Offering
8.2.3. By Process
8.2.4. By Technology
8.2.5. By Application
8.2.6. By Country
8.3. South America: Country Analysis
8.3.1. Brazil Cell and Gene Therapy Manufacturing QC Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Therapy Type
8.3.1.2.2. By Offering
8.3.1.2.3. By Process
8.3.1.2.4. By Technology
8.3.1.2.5. By Application
8.3.2. Argentina Cell and Gene Therapy Manufacturing QC Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Therapy Type
8.3.2.2.2. By Offering
8.3.2.2.3. By Process
8.3.2.2.4. By Technology
8.3.2.2.5. By Application
8.3.3. Colombia Cell and Gene Therapy Manufacturing QC Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Therapy Type
8.3.3.2.2. By Offering
8.3.3.2.3. By Process
8.3.3.2.4. By Technology
8.3.3.2.5. By Application
9. MIDDLE EAST AND AFRICA CELL AND GENE THERAPY MANUFACTURING QC MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Therapy Type
9.2.2. By Offering
9.2.3. By Process
9.2.4. By Technology
9.2.5. By Application
9.2.6. By Country
9.3. MEA: Country Analysis
9.3.1. South Africa Cell and Gene Therapy Manufacturing QC Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Therapy Type
9.3.1.2.2. By Offering
9.3.1.2.3. By Process
9.3.1.2.4. By Technology
9.3.1.2.5. By Application
9.3.2. Saudi Arabia Cell and Gene Therapy Manufacturing QC Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Therapy Type
9.3.2.2.2. By Offering
9.3.2.2.3. By Process
9.3.2.2.4. By Technology
9.3.2.2.5. By Application
9.3.3. UAE Cell and Gene Therapy Manufacturing QC Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Therapy Type
9.3.3.2.2. By Offering
9.3.3.2.3. By Process
9.3.3.2.4. By Technology
9.3.3.2.5. By Application
10. MARKET DYNAMICS
10.1. Drivers
10.2. Challenges
11. MARKET TRENDS & DEVELOPMENTS
11.1. Merger & Acquisition (If Any)
11.2. Product Launches (If Any)
11.3. Recent Developments
12. PESTLE ANALYSIS
13. PORTER’S FIVE FORCES ANALYSIS
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Product
14. COMPETITIVE LANDSCAPE
14.1. Bio-Techne Corporation
14.1.1. Business Overview
14.1.2. Company Snapshot
14.1.3. Products & Services
14.1.4. Financials (As Reported)
14.1.5. Recent Developments
14.1.6. Key Personnel Details
14.1.7. SWOT Analysis
14.2. Biomerieux SA
14.3. F. Hoffmann-La Roche Ltd
14.4. Lonza Group Ltd.
14.5. Miltenyi Biotec India Pvt Ltd.
14.6. Sartorius AG
14.7. Thermo Fisher Scientific Inc.
14.8. AGC Inc.
14.9. Charles River Laboratories International, Inc.
14.10. Merck KGaA
15. STRATEGIC RECOMMENDATIONS
16. ABOUT US & DISCLAIMER
